NCT07780513 Genetic of Skeletal Muscle Insulin Resistance
| NCT ID | NCT07780513 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Condition | Insulin Stimulated |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-08-31 |
| Primary Completion | 2031-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-08-31 with a primary completion date of 2031-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators will use euglycemic/hyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) to reveal cell type-specific molecular response quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.
Eligibility Criteria
Inclusion Criteria: * Males and Females Age 18-75 * Body Mass Index (BMI) \> 18 * Normal glucose tolerance as defined by: Fasting blood sugar \< 100 mg/dL 2-hour Oral Glucose Tolerance Test (OGTT) \< 140mg/dL Stable weight over the past 3 months defined as \>±5% change in body weight * Hemoglobin A1c \< 5.7 * Creatinine \< 2 * Aspartate aminotransferase/Alanine transaminase (AST/ALT) \< 75 * Blood sodium 135 to 145 mEq/L * Blood potassium 3.6 to 5.2 mmol/L\[MH1.1\] Exclusion Criteria: * Urine albumin excretion\>300mg/day * Partial thromboplastin time (PTT) \>35International normalized ratio (INR) \> 1.2 * No oral corticosteroids for 1 month * No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months * No glucagon-like peptide-1 (GLP-1) receptor agonist for 6 months * Any anti-platelet or anti-coagulation medication other than as needed for Pain Management * No alcohol 4 days before the insulin clamp and biopsy procedure * No acute structural knee injuries * No Rheumatologic muscular or nervous system disease * Pregnancy, Intentions to become pregnant, or Breastfeeding * Blood Pressure \>170/110 * Temperature \> 100F * Triglycerides \> 400 by lipid panel * Hemoglobin \<10g/dL * 1+ or greater Blood on Urinalysis * 2+ or greater Protein on Urinalysis * Electrocardiogram (EKG) abnormalities, including but not limited to ST elevations, T wave abnormalities, evidence of recent prior infarct
Contact & Investigator
Luke Norton, PhD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center at San Antonio
Frequently Asked Questions
Who can join the NCT07780513 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Insulin Stimulated. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07780513 currently recruiting?
Yes, NCT07780513 is actively recruiting participants. Contact the research team at nortonl@uthscsa.edu for enrollment information.
Where is the NCT07780513 trial being conducted?
This trial is being conducted at San Antonio, United States.
Who is sponsoring the NCT07780513 clinical trial?
NCT07780513 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Luke Norton, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 100 participants.